LOS ANGELES, CA--(Marketwire - Oct 25, 2011) - Shares of micro-cap biotech TapImmune, Inc. (OTCBB: [ TPIV ]) have seen a steady increase in volume and trading activity in recent weeks. On Friday, the [ company announced ] that its Chairman and CEO, Dr. Glynn Wilson, was invited to be a Key Note Speaker at BITeomics' 2nd Annual World Congress on Immunodiseases and Therapy scheduled to be held in [ Guangzhou, China, November 18-20, 2011 ].

On Monday, shares closed 10.53% higher after trading on much higher than usual volume (1.49M versus an average of 109,375) during the regular session.

With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis [ are spreading at an alarming rate in Europe ], investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.

The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and [ BioMedReports continues to expect ] positive developments from the firm, particularly with Dr. Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.

Reached for comment, Dr. Glynn Wilson stated: "One of the greatest problems facing our ability to respond to viral pandemics (e.g. bird flu, and bioterror threats of currently unknown origin) is how to be prepared for such possibilities. We envisage that our TAP approach could be widely applied and stockpiled independently so that it could be used alone or in concert with any vaccine antigens that might be available. Our work on smallpox and TB is only the starting point."

The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.

A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm. [ Scientific American ] recently profiled Poland's work: [ http://www.scientificamerican.com/article.cfm?id=vaccinomics-personal-vaccine ]

TapImmune [ announced in August ] that it is initiating clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer following their recent FDA IND approval for a Phase I HER-2/neu targeted therapeutic vaccine trial in HER-2/neu positive breast cancer patients at the Mayo Clinic.

For more breaking news and analysis of the Healthcare sector, visit BioMedReports.Com.

Investors interested in make more profitable trades can access BioMedReports' new Complete Database of Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions at:

[ http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html ]

News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com